PT-141 (Bremelanotide)

FDA Approved
Sexual Health
PT-141 (Bremelanotide)

An FDA-approved melanocortin receptor agonist that treats hypoactive sexual desire disorder by acting directly on the central nervous system.

Administration

Subcutaneous injection

Dosage Range

1.75 mg as needed (45 min before activity)

Mechanism of Action

PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, directly stimulating sexual desire pathways in the brain rather than acting on vascular mechanisms like PDE5 inhibitors.

Clinical Benefits

Increases sexual desire and arousal
Works through central nervous system
Effective for both men and women
Does not require vascular function
FDA-approved safety profile

Clinical Evidence

FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. RECONNECT trials demonstrated significant improvement in sexual desire and distress scores.

Side Effects

Nausea (40%)
Flushing
Headache
Injection site reactions
Transient hypertension

Contraindications

Uncontrolled hypertension
Cardiovascular disease
Pregnancy
Not for daily use

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Peptide therapy should only be administered under the supervision of a qualified healthcare provider. Always consult your physician before starting any new treatment protocol.